The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted ...
The American Society of Hematology/ASH 2025 meeting included AML results from AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies.
7don MSN
Aza–ven combination outperforms standard care in AML patients eligible for intensive chemotherapy
In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen ...
Panelists discuss how AML treatment has entered an exciting era of personalized medicine with increasing oral options and ...
Azacitidine plus venetoclax significantly improved multiple outcomes for certain patients with acute myeloid leukemia ...
Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger ...
SLS009 in combination with AZA/VEN achieved a 46% overall response rate across all cohorts, a 58% overall response rate in patients with one ...
InvestorsHub on MSN
Evaxion Biotech gains after unveiling encouraging AML vaccine findings
Evaxion Biotech AS (NASDAQ:EVAX) climbed 4.2% in Monday’s premarket session after sharing new preclinical data supporting its ...
Acute myeloid leukemia (AML) is a type of blood and bone marrow cancer. AML can affect people of any age, but it is most common in adults. AML occurs when bone marrow produces abnormal blood cells, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback